Innocan Pharma is a pharmaceutical company focused on developing patent-pending cannabinoid delivery systems.
LPT CBD is a loaded liposome platform with exact dosing, prolonged and controlled release of CBD into the bloodstream. The platform is in the preclinical trial phase for epilepsy and pain management. Ensures prolonged and controlled release of CBD into the bloodstream for at least 42 days after one injection.
The IP portfolio in this category is part of a joint venture with Yissum, The Hebrew University of Applied Sciences.
CLX CBD is a loaded exosomes platform which is expected to provide the effect of regenerating and anti-inflammatory properties targeting the recovery of infected lung cells and the central nervous system.
The IP portfolio in this category is part of a joint venture with Ramot, Tel Aviv University of Applied Sciences.
In the field of premium dermal cosmetics in areas such pain relief, dermatology and vaginal atrophy, Innocan is aiming to establish IP protection towards the markets of North and South America, Europe and Asia. Products are now trademarked and distributed in Canada, France, the UK, Germany, Portugal, Italy and Poland.
After using Innocan’s Relief & Go Spray 83% of participants noticed immediate improvement in pain after 20 minutes.
Ayurcann produces topicals for the company.
PARTNERSHIPS:
2019
The company signed an agreement with Fancystage Unipessoal LDA that will produce GMP-CBD cosmetics under the InnoCan brand for the European market.
2020
The company signed its first distribution agreement with Active Therapeutics for InnoCan’s CBD dermacosmetics products in the UK and Ireland.
The company developed a new line of CBD products for Tamar Technologies that the company will manufacture and market under Tamar’s brand and Tamar will be in charge of regulatory approvals, branding, sales and distribution.
The company entered into a 1-year exclusive manufacturing and distribution agreement with Endless Sky Incorporated who will serve as the exclusive distributor of Innocan’s CBD products in Canada through a licensing agreement with a license fee as well as royalties based on the net sales. The agreement will automatically be exnteded for another year if minimum sales are reached.
The company enetered into a distribution agreement with iAmHealth Distribution UG for the sales of its SHIR Beauty and Relief & Go product lines in Germany.
The company entered into a distribution agreement Cloud 9 Switzerland to sell the company’s SHIR Beauty and Relief & Go product lines in Italy and Switzerland.
2021
The company announced an exclusive distribution agreement with Polyflame for the distribution of the company’s SHIR and Relief & Go brands in France with a purchase forecast of 600,000 EUR per year.
The company signed an exclusive distribution agreement with Health Investment Group S.A. for the company’s SHIR and Relief & Go brands in Poland.
The company announced an exclusive manufacturing and distribution agreement with Ayurcann Inc for the manufacture and distribution of the company’s Relief and Go and SHIR lines of topicals for the Canadian market. Ayurcann will pay the company royalties based on net sales of the products
2023
The company announced that it had entered into a multi-year distribution agreement with UAB Medexy and under this agreement, UAB Medexy has the exclusive right to distribute both Innocan’s SHIR and RELIEF&GO brands in Lithuania, Latvia and Estonia on the basis of an agreed purchase forecast. UAB Medexy’s first order under the distribution agreement included more than 5000 units of SHIR and RELIEF&GO products.
The company received its first patent in the US for its proprietary cannabis and magnesium-based pain relief topicals under patent number 16/968,627.
2025
The company received a patent in India for its liposome CBD injection platform.
The company was granted a patent in Mexico for its blend of CBD with minerals delivering a fast acting, targeted pain relief.